<root>
	<PMID Version="1">25893930</PMID>
	<Summary>
		1: Gontero P, Marra G, Soria F, Oderda M, Zitella A, Baratta F, Chiorino G,Gregnanin I, Daniele L, Cattel L, Frea B, Brusa P. A randomized double-blindplacebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or"chemopromotion"? Prostate. 2015 Aug 1;75(11):1177-86. doi: 10.1002/pros.22999.Epub 2015 Apr 20. PubMed PMID: 25893930.
	</Summary>
	<MeshHeadingList>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D016588">Anticarcinogenic Agents</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D002338">Carotenoids</DescriptorName>
			<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D018890">Chemoprevention</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D019587">Dietary Supplements</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D016903">Drug Monitoring</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="Y" UI="D011467">Prostate</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
			<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D017430">Prostate-Specific Antigen</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="Y" UI="D019048">Prostatic Intraepithelial Neoplasia</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
			<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
			<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="Y" UI="D011471">Prostatic Neoplasms</DescriptorName>
			<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
			<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
			<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp;amp; control</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D012643">Selenium</DescriptorName>
			<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
	    </MeshHeading>
	    <MeshHeading>
			<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
	    </MeshHeading>
	</MeshHeadingList>
</root>
